Table 3.

Characterization of Patients Showing Atherogenesis-Related Vascular Complications

Patients3-150Sex/Age Blood Transfusions Per YearFerritin3-151 (ng/mL) Vascular Complication LDL-CD3-151 (nmol/mg LDL prot) Plasma MDA3-151 (nmol/mL)
1  M/33  6 1,100  Ulcerative peripheral vasculopathy  36.26  3.00 
2  F/29  6  950  Severe cerebral ischemia  48.33 2.31  
3  M/41  <3  1,350  Pulmonary hypertension 34.7  2.51  
    Retinal vasculopathy  
4 M/31  6  1,050  Pulmonary hypertension  31.94  1.65 
5  F/42  <3  750  Severe cerebral ischemia  39.58 1.81  
6  M/27  <3  450  Pulmonary hypertension 31.17  1.80  
7  F/12  <3  450  Pulmonary hypertension  30.7  1.70  
8  M/34  <3  1,900 Pulmonary hypertension  41.6  1.80 
    Retinal vasculopathy  
9  M/40  <3 900  Pulmonary hypertension  45.38  2.90 
Patients3-150Sex/Age Blood Transfusions Per YearFerritin3-151 (ng/mL) Vascular Complication LDL-CD3-151 (nmol/mg LDL prot) Plasma MDA3-151 (nmol/mL)
1  M/33  6 1,100  Ulcerative peripheral vasculopathy  36.26  3.00 
2  F/29  6  950  Severe cerebral ischemia  48.33 2.31  
3  M/41  <3  1,350  Pulmonary hypertension 34.7  2.51  
    Retinal vasculopathy  
4 M/31  6  1,050  Pulmonary hypertension  31.94  1.65 
5  F/42  <3  750  Severe cerebral ischemia  39.58 1.81  
6  M/27  <3  450  Pulmonary hypertension 31.17  1.80  
7  F/12  <3  450  Pulmonary hypertension  30.7  1.70  
8  M/34  <3  1,900 Pulmonary hypertension  41.6  1.80 
    Retinal vasculopathy  
9  M/40  <3 900  Pulmonary hypertension  45.38  2.90 
F3-150

No patient was a smoker.

F3-151

Values are the mean of two determinations performed in duplicate on blood samples and homologous LDL during 1 year of observation.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal